‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The Federal Trade Commission and seven states say Shkreli should be held in contempt
Read Full Article on MarketWatchAI SUMMARY
# Summary Martin Shkreli faces contempt charges from the FTC and seven states for allegedly violating a ban on influencing biopharma stocks, potentially signaling stricter regulatory enforcement against market manipulation in the pharmaceutical sector. The case could result in significant penalties and set precedent for how regulators pursue individuals engaged in coordinated stock manipulation schemes.
More Top Stories News
‘I am a pretty cautious person’: My financial adviser wants me to invest $350,000 in a UAE data center. Is this risky?
My wife says we can’t afford to retire, yet she wants to take an $8,000 trip to Italy. We have $4 million. Do I keep working?
Who should pay for a birthday dinner? I always treat my guests.
Hedge-fund legend Paul Tudor Jones says the stock market faces a really challenging 2027. Here’s why.
Six Flags’ stock slumps toward 16-year low after fatal incident
Content sourced from MarketWatch. Not financial advice.